CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients

Therapeutic Drug Monitoring

Volumn 22, Issue 4, 2000, Pages 392-396

  Shimoda, Kazutaka ^a   Morita, Sachiyo ^a   Yokono, Aya ^a,b   Someya, Toshiyuki ^c   Hirokane, Genta ^a,d   Sunahara, Noriyuki ^e   Takahashi, Saburo ^f  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Hachiman Seijukai Hospital   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d Takashima General Hospital   (Japan)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^f Saitama Kounan Hospital   (Japan)

Author keywords

Cytochrome P450(CYP)2D6; Genotype; Haloperidol

Indexed keywords

CYTOCHROME P450; HALOPERIDOL; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT;

ADULT; ARTICLE; ASIAN; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; GENE MUTATION; GENE NUMBER; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; AGED; ALLELE; BLOOD; GENETICS; JAPAN; MIDDLE AGED; MUTATION; SMOKING;

ADULT; AGED; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; HALOPERIDOL; HUMANS; JAPAN; MALE; MIDDLE AGED; MUTATION; SMOKING;

EID: 0033624471     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200008000-00005     Document Type: Article

References (24)

1. Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6 (sparteine/debrisoquine monooxygenase)
2. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
3. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
4. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders
5. Genetic analysis of the Chinese cytochrome P4502D6 locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation
6. Effect of anticonvulsants on plasma haloperidol and thioridazine levels
7. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite
8. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
9. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
10. Basic evaluation of enzyme immunoassay for haloperidol level and its clinical application
11. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
12. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
13. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population
14. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients
15. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
16. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes
17. Coadministration of fluvoxamine increases serum concentrations of haloperidol
18. Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
19. Haloperidol reductase in human and guinea pig livers
20. Use of antisera in the isolation of human specific conjugate of haloperidol
21. Lower plasma levels of haloperidol in smoking than in non-smoking schizophrenic patients
22. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol
23. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation
24. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implication for the involvement of cytochrome P450IID6